跳至主要内容
临床试验/NCT01558505
NCT01558505已完成4 期

Drug Eluting Balloon in peripherAl inTErvention For Below The Knee Angioplasty Evaluation: the DEBATE-BTK Study

Leonardo Bolognese, MD1 个研究点 分布在 1 个国家目标入组 142 人开始时间: 2010年11月1日最近更新:
适应症
干预措施

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
142
试验地点
1
主要终点
angiographic binary restenosis

研究概览

简要总结

Drug-eluting balloon showed positive results in terms of restenosis reduction in peripheral intervention (PTA). The aim of the study is to investigate in a randomized fashion the efficacy and safety of Paclitaxel-eluting balloon (PEB) (In.Pact Amphirion, Invatec, Brescia, Italy) versus non drug-eluting balloon (NEB) (Amphirion deep, Invatec, Brescia, Italy) in diabetic patients with Critical Limb Ischemia (CLI) undergoing PTA of below-the-knee (BTK) vessels.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •age>18 years
  • •angiographic stenosis>50% or occlusion of one below-knee vessel

排除标准

  • •allergy to Paclitaxel
  • •contraindication for combined antiplatelet treatment
  • •life expectancy <1 year
  • •hypersensitivity or contraindication to one of the study drugs
  • •lack of consent
  • •need for amputation

研究组 & 干预措施

standard PTA

Active Comparator

conventional balloon angioplasty

干预措施: POBA (Device)

Drug-eluting balloon angioplasty

Experimental

paclitaxel-eluting balloon angioplasty

干预措施: PEB (Device)

结局指标

主要结局

angiographic binary restenosis

时间窗: 12 months

incidence of binary restenosis

次要结局

  • major amputation(24 motnhs)
  • target lesion revascularization(24 months)
  • vessel reocclusion(24 months)

研究者

发起方
Leonardo Bolognese, MD
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Leonardo Bolognese, MD

Director

Ospedale San Donato

研究点 (1)

Loading locations...

相似试验